PL416359A1 - Przeciwciała monoklonalne rozpoznające swoiście psi antygen DLA-DR i ich zastosowania - Google Patents

Przeciwciała monoklonalne rozpoznające swoiście psi antygen DLA-DR i ich zastosowania

Info

Publication number
PL416359A1
PL416359A1 PL416359A PL41635916A PL416359A1 PL 416359 A1 PL416359 A1 PL 416359A1 PL 416359 A PL416359 A PL 416359A PL 41635916 A PL41635916 A PL 41635916A PL 416359 A1 PL416359 A1 PL 416359A1
Authority
PL
Poland
Prior art keywords
canine
dla
antigen
monoclonal antibodies
antibodies specifically
Prior art date
Application number
PL416359A
Other languages
English (en)
Other versions
PL234632B1 (pl
Inventor
Arkadiusz Miążek
Marta Lisowska
Andrzej Rapak
Original Assignee
Inst Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk filed Critical Inst Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk
Priority to PL416359A priority Critical patent/PL234632B1/pl
Priority to RS20210766A priority patent/RS62002B1/sr
Priority to SI201730809T priority patent/SI3423497T1/sl
Priority to US16/076,801 priority patent/US11274161B2/en
Priority to HUE17760377A priority patent/HUE055076T2/hu
Priority to ES17760377T priority patent/ES2875550T3/es
Priority to PCT/PL2017/050014 priority patent/WO2017151000A1/en
Priority to LTEP17760377.6T priority patent/LT3423497T/lt
Priority to EP17760377.6A priority patent/EP3423497B1/en
Publication of PL416359A1 publication Critical patent/PL416359A1/pl
Publication of PL234632B1 publication Critical patent/PL234632B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem zgłoszenia są przeciwciała monolokalne oraz ich fragmenty rozpoznające swoiście psi antygen DLA - DRB. Zgłoszenie obejmuje także ich zastosowanie w leczeniu, profilaktyce lub diagnostyce białaczki, zwłaszcza psiej.
PL416359A 2016-03-02 2016-03-02 Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania PL234632B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL416359A PL234632B1 (pl) 2016-03-02 2016-03-02 Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania
RS20210766A RS62002B1 (sr) 2016-03-02 2017-03-02 Monoklonska antitela koja posebno prepoznaju pseći dla-dr antigen i njihova upotreba
SI201730809T SI3423497T1 (sl) 2016-03-02 2017-03-02 Monoklonska protitelesa, ki specifično prepoznajo pasji DLA-DR antigen in njihove uporabe
US16/076,801 US11274161B2 (en) 2016-03-02 2017-03-02 Monoclonal antibodies that specifically recognize canine DLA-DR antigen and their uses
HUE17760377A HUE055076T2 (hu) 2016-03-02 2017-03-02 Kutya DLA-DR antigént specifikusan felismerõ monoklonális ellenanyagok és alkalmazásuk
ES17760377T ES2875550T3 (es) 2016-03-02 2017-03-02 Anticuerpos monoclonales que reconocen específicamente el antígeno DLA-DR de canino y sus usos
PCT/PL2017/050014 WO2017151000A1 (en) 2016-03-02 2017-03-02 Monoclonal antibodies that specifically recognize canine dla-dr antigen and their uses
LTEP17760377.6T LT3423497T (lt) 2016-03-02 2017-03-02 Monokloniniai antikūnai, kurie specifiškai atpažįsta šunų dla-dr antigeną, ir jų panaudojimas
EP17760377.6A EP3423497B1 (en) 2016-03-02 2017-03-02 Monoclonal antibodies that specifically recognize canine dla-dr antigen and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL416359A PL234632B1 (pl) 2016-03-02 2016-03-02 Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania

Publications (2)

Publication Number Publication Date
PL416359A1 true PL416359A1 (pl) 2017-09-11
PL234632B1 PL234632B1 (pl) 2020-03-31

Family

ID=59744222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL416359A PL234632B1 (pl) 2016-03-02 2016-03-02 Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania

Country Status (9)

Country Link
US (1) US11274161B2 (pl)
EP (1) EP3423497B1 (pl)
ES (1) ES2875550T3 (pl)
HU (1) HUE055076T2 (pl)
LT (1) LT3423497T (pl)
PL (1) PL234632B1 (pl)
RS (1) RS62002B1 (pl)
SI (1) SI3423497T1 (pl)
WO (1) WO2017151000A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116997568A (zh) * 2021-02-03 2023-11-03 新加坡科技研究局 抗原结合分子及其方法ii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340898C (en) 1987-04-30 2000-02-15 The Wistar Institute Monoclonal antibodies against lymphoma-associated antigens, hybrid cell lines producing these antibodies, and use therefore
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN102690789B (zh) 2012-04-28 2013-06-19 中国人民解放军第三军医大学 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
WO2017151000A1 (en) 2017-09-08
SI3423497T1 (sl) 2021-11-30
PL234632B1 (pl) 2020-03-31
RS62002B1 (sr) 2021-07-30
ES2875550T3 (es) 2021-11-10
EP3423497A4 (en) 2019-03-06
US11274161B2 (en) 2022-03-15
EP3423497B1 (en) 2021-04-14
HUE055076T2 (hu) 2021-10-28
US20190144560A1 (en) 2019-05-16
EP3423497A1 (en) 2019-01-09
LT3423497T (lt) 2021-08-25

Similar Documents

Publication Publication Date Title
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
PH12021550152A1 (en) Anti-cd112r compositions and methods
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
ZA201902743B (en) Antibodies and polypeptides directed against cd127
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
ZA201708265B (en) Tigit-binding agents and uses thereof
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
MX2019008551A (es) Anticuerpos anti-tgf-beta y su uso.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
MX2019008348A (es) Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
PL3176181T3 (pl) Przeciwciało monoklonalne anty-CTLA4 lub jego fragment wiążący antygen, kompozycja lecznicza i zastosowanie
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2018069871A3 (en) Anti-kras binding proteins
IL262404A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use